Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

PDLI / PDL BioPharma, Inc. EXHIBIT 99.1

12h sec.gov
Exhibit Exhibit 99.1 PDL BioPharma Terminates Interest in Pursuing Acquisition of Neos -- PDL does not plan to make any further proposals to acquire Neos -- INCLINE VILLAGE, NV, February 20, 2018 -- PDL BioPharma, Inc. (NASDAQ: PDLI) today officially announced it will no longer pursue its proposed acquisition of Neos Therapeutics, Inc. (NASDAQ: NEOS). While PDL’s last public disclosure announced its proposal expired on November 8, 2017, PDL has maintained its interest until recently making the d (10-0)

PDLI / PDL BioPharma, Inc. 8-K (Current Report)

12h sec.gov
Document     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 20, 2018 PDL BioPharma, Inc. (Exact name of Company as specified in its charter) 000-19756 (Commission File Number) Delaware   94-3023969 (State or Other Jurisdiction of Incorporation)   (I. (10-0)

PDLI / PDL BioPharma, Inc. / STATE STREET CORP - PDL BIOPHARMA, INC. (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING PDL BIOPHARMA, INC. (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 69329Y104 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL

PDLI / PDL BioPharma, Inc. / STATE STREET CORP - PDL BIOPHARMA, INC. (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING PDL BIOPHARMA, INC. (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 69329Y104 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL

PDLI / PDL BioPharma, Inc. / Renaissance Technologies LLC - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* PDL BIOPHARMA, INC. ---------------------------------------------------------------------------- (Name of Issuer) Common Stock ---------------------------------------------------------------------------- (Title of Class of Securities) 69329Y104 ---------------------------------------------------------------------------- (CUSIP Number) December 29, 2017

PDLI / PDL BioPharma, Inc. / Renaissance Technologies LLC - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* PDL BIOPHARMA, INC. ---------------------------------------------------------------------------- (Name of Issuer) Common Stock ---------------------------------------------------------------------------- (Title of Class of Securities) 69329Y104 ---------------------------------------------------------------------------- (CUSIP Number) December 29, 2017

PDLI / PDL BioPharma, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
pdlbiopharmainc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 5 )*       Name of issuer:  PDL BioPharma Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  69329Y104     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule

PDLI / PDL BioPharma, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
pdlbiopharmainc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 5 )*       Name of issuer:  PDL BioPharma Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  69329Y104     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule

PDLI / PDL BioPharma, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G (Passive Investment)

2018-02-09 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No.   )*       PDL BIOPHARMA INC (Name of Issuer)   Common Stock (Title of Class of Securities)     69329Y104                                 (CUSIP Number)                                   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule i

PDLI / PDL BioPharma, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G (Passive Investment)

2018-02-09 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No.   )*       PDL BIOPHARMA INC (Name of Issuer)   Common Stock (Title of Class of Securities)     69329Y104                                 (CUSIP Number)                                   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule i

PDL BioPharma Has More Cash Than Its Market Cap

2018-02-06 seekingalpha
Editor's note: Seeking Alpha is proud to welcome Brad Burke as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Pro. Click here to find out more » (62-1)

Protagonist Therapeutics started at buy with $32 stock price target at Stifel Nicolaus

2018-01-29 marketwatch
Penumbra's (PEN) joint venture with Sixense Enterprises indicates formation of a leading digital health platform in the field of virtual reality technology. (84-1)

PDLI / PDL BioPharma, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-23 fintel.io
PDL BioPharma, Inc. (NASDAQ:PDLI) has 189 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 139,873,408 shares. Largest shareholders include BlackRock Inc., Vanguard Group Inc, Renaissance Technologies LLC, Dimensional Fund Advisors Lp, State Street Corp, Acadian Asset Management Llc, Mackenzie Financial Corp, Aqr Capital Management Llc, Millennium Management Llc, and Northern Trust Corp. (55-1)

PDLI / PDL BioPharma, Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-23 sec.gov
us69329y1047_012318.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) PDL BIOPHARMA INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 69329Y104 -------------------------------------------------------- (CUSIP Number) December 31, 2017 ----------------------------------------------------

PDLI / PDL BioPharma, Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-23 sec.gov
us69329y1047_012318.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) PDL BIOPHARMA INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 69329Y104 -------------------------------------------------------- (CUSIP Number) December 31, 2017 ----------------------------------------------------


CUSIP: 69329Y104